
Please try another search
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Name | Age | Since | Title |
---|---|---|---|
Donald A. Wuchterl | 54 | 2021 | Independent Director |
Steven Gray | - | 2017 | Member of Scientific Advisory Board |
Michael Amoroso | 46 | 2020 | Chairman of the Board |
Vishwas Seshadri | 48 | 2021 | President, CEO & Director |
Mark J. Alvino | 56 | 2021 | Independent Director |
Jonathon Mink | - | 2017 | Member of Scientific Advisory Board |
John Cooper | - | 2017 | Member of Scientific Advisory Board |
Leila Alland | 61 | 2021 | Independent Director |
Christine Berni-Silverstein | 41 | 2016 | Independent Director |
Faith L. Charles | - | 2021 | Independent Director |
Bernhardt G. Zeiher | 60 | 2024 | Independent Director |
Eric Crombez | 51 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review